PositoAI/ US/ Avalyn Pharma Inc.

Avalyn Pharma Inc.

NasdaqGS: AVLN · Healthcare

Positivity Index

#4,734 / 6,774

Global

#2,447 / 4,000

United States

Positivity Score

19,038

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Avalyn Pharma Inc. — Overview & Financial Snapshot

Avalyn Pharma Inc. (NasdaqGS: AVLN) is a Healthcare company, ranked #4,734 of 6,774 companies globally and #2,447 of 4,000 in United States on PositoAI, with a Positivity Score of 19,038. Its market capitalisation is ₹11,403.14 Cr ($1.21B), P/E ratio is -11.0 and P/B ratio is 3.03. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

P/B Ratio 3.03

P/E Ratio -11.0

D/E Ratio 0.04

ROE —

Owes vs Owns ? 0.06× Low $0.06 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-233.15$-2.47

Forward EPS ₹-243.53$-2.58

Beta —

Market Cap ₹11,403.14 Cr$1.21B

What these numbers mean →

What does Avalyn Pharma Inc. do?

What is Avalyn Pharma Inc.'s P/E and P/B ratio?

Avalyn Pharma Inc. has a P/E ratio of -11.0 and a P/B ratio of 3.03.

What is Avalyn Pharma Inc.'s debt-to-equity ratio?

Avalyn Pharma Inc. has a debt-to-equity ratio of 0.04.

How much does Avalyn Pharma Inc. owe compared with what it owns?

Avalyn Pharma Inc. owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Avalyn Pharma Inc.'s Positivity rank?

Avalyn Pharma Inc. is ranked #4,734 of 6,774 companies globally and #2,447 of 4,000 in United States on PositoAI, with a Positivity Score of 19,038.

Does Avalyn Pharma Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Avalyn Pharma Inc..

Where can I read the latest news about Avalyn Pharma Inc.?

Recent headlines about Avalyn Pharma Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Avalyn Pharma Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Avalyn Pharma Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.